• 04 May 2026
• Admin
• News Article

FDA Puts Temporary Hold on Newron’s Phase III Schizophrenia Trial — Here’s What It Actually Means

Clinical trials don’t fail quietly. Sometimes, they pause.

That’s exactly what’s happened with Newron Pharmaceuticals SpA and its late-stage schizophrenia program.

What Happened: A Regulatory Pause, Not a Shutdown

The U.S. Food and Drug Administration (FDA) has placed a hold on new patient enrollment in U.S. sites for the Phase III ENIGMA-TRS 2 trial.

Key detail most people miss:

• This is not a full clinical hold
• It only affects new enrollments in U.S. sites
• Ongoing patients and global trials continue

Why the pause?

• A sudden death occurred in a trial participant
• The event happened outside the U.S.
• Investigators deemed it unrelated to the drug

Still, regulators don’t take chances.

The Drug at the Center: Evenamide

Newron’s lead candidate, evenamide, targets a different pathway than traditional antipsychotics.

Instead of dopamine, it focuses on glutamate modulation.

Why that matters:

• Schizophrenia isn’t fully controlled by dopamine-targeting drugs
• Many patients don’t respond adequately
• Treatment-resistant schizophrenia (TRS) remains a major gap

Evenamide is positioned as:

• A first-in-class glutamate modulator
• A potential add-on therapy
• Designed for treatment-resistant patients

That’s a high-value, high-risk space.

Safety Signal or Statistical Reality?

Here’s where nuance matters.

• Independent safety board reviewed the case
• Conclusion: trials should continue as designed
• No observed increase in mortality vs placebo so far

Context matters:

• Schizophrenia patients have 10–25 years lower life expectancy
• Sudden unexpected death accounts for ~20% of mortality

Translation:
A single event doesn’t equal a drug-related risk—but it must be investigated.

Status of the ENIGMA Program

ENIGMA-TRS 1 (Global Study)

• Ongoing across 21 countries
• 400+ patients enrolled
• Target: 600 patients
• 52-week study duration
• Primary endpoint: PANSS score change at 12 weeks
• Expected readout: Q4 2026

ENIGMA-TRS 2 (U.S. + Select Markets)

• Focused 12-week Phase III study
• ~400 patients planned
• Evaluating 15 mg BID dose
• Approved in:
  • India
  • Argentina
• Pending approvals:
  • Colombia
  • Malaysia

Only U.S. enrollment is paused. The rest continues.

What Newron Is Doing Now

Newron is taking the standard (and necessary) route:

• Working closely with the FDA
• Submitting additional safety data
• Aiming to lift the hold and resume enrollment

No pivot. No panic. Just regulatory process.

The Bigger Picture: High Stakes in TRS

Treatment-resistant schizophrenia is where many drugs fail.

Why?

• Patients are already on second-generation antipsychotics
• Many are on clozapine, the last-line therapy
• Incremental improvements are hard to achieve

Evenamide’s early data suggests:

• Symptom improvement increases over time
• Favorable safety profile (so far)
• Potential differentiation vs existing options

But Phase III is where optimism gets tested.

Commercial and Strategic Context

Newron isn’t building alone.

• Partnered with EA Pharma for Japan and Asia
• Partnered with Myung In Pharm for South Korea

It also has a marketed CNS product:

• Safinamide (Xadago)
  • Used in Parkinson’s disease
  • Commercialized globally via partners

So this isn’t a one-shot company—but evenamide is clearly the value driver.

The Bottom Line

This is a speed bump, not a derailment.

• The hold is localized and precautionary
• Independent review supports continuation
• No clear signal yet of drug-related risk

But don’t downplay it either. Late-stage CNS trials are fragile. Regulatory scrutiny only intensifies from here. The real inflection point? Q4 2026, when efficacy data lands. That’s when evenamide either proves it belongs—or doesn’t.